Skip to main content
Premium Trial:

Request an Annual Quote

INCAPS, Four Pharmas Form Neuroproteomics Consortium; Cancer Project to Follow

NEW YORK, April 5 (GenomeWeb News) - INCAPS - the Indiana Centers for Applied Protein Sciences - and four unnamed pharmaceutical companies have formed a consortium to explore the effect of disease and drug reaction in the central nervous system, INCAPS said today.

 

The fee-for-service research organization said that the focus of the project, called the Neuroproteomics Consortium, is to study neurodegenerative diseases, such as Alzheimer's disease, but that future consortiums on disease areas such as cancer are being planned.

 

Laurie Caviston, INCAPS' vice president of business development, sales and marketing, said that the consortium is a self-funded group, and that the projects will take advantage of commercially available mass spectrometry technology.

 

Caviston declined to provide GenomeWeb News with the identities of the pharmaceutical companies involved, but said that the consortium could make a formal announcement later this month.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.